Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.
Enterolactone, a phytoestrogen belonging to the class of lignans, is produced by the intestinal microflora from precursors in plant foods and has been implicated in protection against cancer. We study the effect of enterolactone on the risk of a subsequent diagnosis of prostate cancer. We conducted a longitudinal, nested case-control study by linkage of 3 biobanks to the cancer registries in Finland, Norway and Sweden, respectively. Enterolactone concentrations were measured by time-resolved fluoroimmunoassay in serum from 794 men who had a diagnosis of prostate cancer at a mean follow-up time of 14.2 years after blood collection and among 2,550 control men matched within each cohort for age (+/-2 years), date of blood collection (+/-2 months) and county. The median enterolactone concentrations did not differ between case and control subjects in the full study group (8.4 nmol/L [25th-75th percentile = 4.5-15.0] vs. 8.5 nmol/L [25th-75th percentile = 4.3-15.9]), nor in the national groups. Odds ratios of prostate cancer risk estimated by conditional logistic regression for increasing concentrations of enterolactone in quartiles in the full study group were 1.00 (referent), 1.21 (95% confidence interval [CI] = 0.96-1.52), 1.16 (95% CI = 0.91-1.47) and 1.08 (95% CI = 0.83-1.39). The OR estimate for the highest vs. the lowest quartile of enterolactone in separate analyses of the Norwegian, Finnish and Swedish cohort was 1.21 (95% CI = 0.91-1.60), 1.02 (95% CI = 0.59-1.76) and 0.87 (95% CI = 0.45-1.67), respectively. No support for the hypothesis that high circulating enterolactone is protective against prostate cancer was found.
Stattin
Pär
P
Department of Urology, Umeå University Hospital, Umeå, Sweden.
Adlercreutz
Herman
H
Tenkanen
Leena
L
Jellum
Egil
E
Lumme
Sonja
S
Hallmans
Göran
G
Harvei
Sverre
S
Teppo
Lyly
L
Stumpf
Katariina
K
Luostarinen
Tapio
T
Lehtinen
Matti
M
Dillner
Joakim
J
Hakama
Matti
M
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000097:blood*; D016022:Case-Control Studies; D015331:Cohort Studies; D004967:Estrogens / Q000097:blood; D005387:Finland / Q000453:epidemiology; D015200:Fluoroimmunoassay; D006801:Humans; D017705:Lignans / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009664:Norway / Q000453:epidemiology; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000097:blood / Q000453:epidemiology*; D012307:Risk Factors; D013548:Sweden / Q000453:epidemiology
D004967:Estrogens; D017705:Lignans; D015107:4-Butyrolactone; C029497:2,3-bis(3'-hydroxybenzyl)butyrolactone